Biotech Tweet of the Week: The Best of ASCO Is Yet to Come

On this week's episode of Biotech Banter, senior biotech specialist Brian Orelli and health-care analyst David Williamson discuss the tweet of the week from David Miller of AlpineBioVentures, who says, "Tip for those new to the ASCO thing: Abstracts are less than half the story. Posters & presentations are the real data."

We got a lot of data in the abstracts that were released earlier this month. But as David points, out there's more data to come.

The late-0breaking abstracts won't be released until the meeting begins on Friday. There investors can expect to see phase 2 data on AstraZeneca's (NYSE: AZN  ) ovarian cancer drug olaparib, phase 3 lung cancer data for Eli Lilly's (NYSE: LLY  ) Cyramza, and phase 3 data for Johnson & Johnson (NYSE: JNJ  ) and Pharmacyclics' Imbruvica in elderly patients with CLL. There will also be a couple of high-profile melanoma studies: Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy as an adjuvant therapy after surgery and the use of Merck's (NYSE: MRK  ) MK-3475 in patients who haven't received Yervoy.

Investors can also look forward to expanded data from the abstracts that were released last week. Brian highlights safety data for Bristol-Myers Squibb's Yervoy-PD1 combo that he's looking forward to seeing. Watch the following video for further insight on what to expect at ASCO.

Say hello to ASCO, say goodbye to "Made in China"
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion-dollar industry." And everyone from BMW to Nike to the U.S. Air Force is already using it every day. Watch The Motley Fool's shocking video presentation today to discover the garage gadget that's putting an end to the "Made in China" era, and learn the investing strategy we've used to double our money on these 3 stocks. Click here to watch now!

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2971635, ~/Articles/ArticleHandler.aspx, 9/1/2015 6:29:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Brian Orelli

Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.

Today's Market

updated 9 hours ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 4:05 PM
AZN $31.28 Down -0.39 -1.23%
AstraZeneca plc (A… CAPS Rating: ****
BMY $59.47 Down -1.14 -1.88%
Bristol-Myers Squi… CAPS Rating: ****
JNJ $93.98 Down -1.19 -1.25%
Johnson & Johnson CAPS Rating: ****
LLY $82.35 Down -0.84 -1.01%
Eli Lilly & Co. CAPS Rating: ****
MRK $53.85 Down -1.52 -2.75%
Merck & Co., Inc. CAPS Rating: ****